Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    13

Stocks News & Analysis

stocks

The ultimate investing hack: dividend growth stocks

Finding companies built for lasting dividend growth.
stocks

Is the data centre party over for Goodman?

Global spending spree on data centres could mean a declining return on invested capital.
stocks

Is AUB an opportunity after shares plunge 17%?

After a takeover bid was withdrawn shares dropped to below the pre-bid price.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,894.205.900.07%
CAC 408,076.451.840.02%
DAX 4023,779.8068.940.29%
Dow JONES (US)47,474.46185.130.39%
FTSE 1009,689.0612.74-0.13%
HKSE25,760.73334.32-1.28%
NASDAQ23,413.67137.750.59%
Nikkei 22549,864.68561.231.14%
NZX 50 Index13,582.5479.770.59%
S&P 5006,829.3716.740.25%
S&P/ASX 2008,595.204.900.06%
SSE Composite Index3,878.0019.71-0.51%

Market Movers